The purpose of this study is to assess the safety, tolerability and pharmacokinetics of 4 weeks therapy with FK788 in subjects with chronic hepatitis C virus (HCV) infection. Also, to assess the effect of FK788 on serum ALT concentration and hepatitis C viral level during therapy and for four weeks following therapy.

Start Date01 Oct 2002

Sponsor / Collaborator

Astellas Pharma, Inc.

[+1]

100 Clinical Results associated with FK-788

100 Translational Medicine associated with FK-788

100 Patents (Medical) associated with FK-788

Literatures (Medical) associated with FK-788

01 Sep 2006·Bioorganic & Medicinal Chemistry LettersQ4 · MEDICINE

Metabolism investigation leading to novel drug design 2: Orally active prostacyclin mimetics. Part 5

Q4 · MEDICINE

Article

Author: Jiro Seki ; Kiyoshi Taniguchi ; Hisashi Takasugi ; Fujiko Takamura ; Akira Tanaka ; Mie Nishio ; Kouji Hattori

A metabolism study of FK788 (2) led to the discovery of new diphenylcarbamoyl derivatives as prostacyclin mimetics without the PG skeleton. We designed and evaluated PGI(2) mimetics based on blocking the main metabolic pathway of FK788. The new compound 7c was found to be equipotent to FK788 towards PGI(2) agonist activity and metabolically more stable than FK788.

01 Jun 2005·Bioorganic & Medicinal Chemistry LettersQ4 · MEDICINE

Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: Orally active prostacyclin mimetics. Part 3

Q4 · MEDICINE

Article

Author: Osamu Okitsu ; Jiro Seki ; Masahide Higaki ; Akira Tanaka ; Kouji Hattori ; Seiichiro Tabuchi ; Kiyoshi Taniguchi ; Kazuo Sakane ; Satoshi Koyama ; Mie Nishio

The new classes of diphenylcarbamate derivatives with a tetrahydronaphthalene skeleton as highly potent and selective IP agonists have been discovered. The optimized diphenylcarbamate type compound FK-788: (R)-4 exhibited potent antiaggregative potency with an IC50 of 18 nM and high binding affinity for the human recombinant IP receptor with K(i) values of 20 nM and selectivity for human IP over all other members of the human prostanoid receptor family. Compound (R)-4 was shown to exhibit good pharmacokinetic properties in rats and dogs, and also good bioavailability in healthy volunteers.

100 Deals associated with FK-788

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hepatitis C, Chronic	Phase 2	US	Astellas Pharma, Inc.	01 Oct 2002

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

FK-788

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation